The U.S. Food and Drug Administration issued an emergency use authorization Sunday for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s ongoing efforts to fight COVID-19.
The antibody-rich blood component is taken from patients who have recovered from COVID-19, and Sunday’s action permits use of the treatment on hospitalized COVID-19 patients within three days of diagnosis.
In a Sunday news conference, U.S. President Donald Trump cited the program’s “incredible rate of success” in announcing the FDA’s step for which he credited the removal of “unnecessary barriers and delays, not by cutting corners, but by marshalling the full power of the federal government.”
FDA Commissioner Stephen M. Hahn said during Trump’s Sunday news conference that the medical community is, of course, “waiting for more data,” but called the success rate for the use of convalescent plasma a “pretty substantial clinical benefit.”
Specifically, Health and Human Services Secretary Alex Azar said the data collected to date indicates that patients over the age of 80 and not using artificial respiration who have used the treatment within three days of diagnosis saw a 35% mortality reduction.
“We dream in drug development of something like a 35% mortality reduction,” Azar said.
He also said that 70,000 American patients have already benefited from the treatment to date.
© 2021 Cox Media Group